<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470-7330-14-S1-S2</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-S2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Scientific Session Presentation</subject></subj-group></article-categories><title-group><article-title>Prostate-MRI: experience of the observer and technical conditions influence the cancer detection rate</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Roedel</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>drstroedel@aol.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Blaut</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Duerig</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Burke</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Paulick</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Haroske</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Steinbach</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Kittner</surname><given-names>T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Krankenhaus Dresden-Friedrichstadt</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>S2</fpage><lpage>S2</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Roedel et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Roedel et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/S2"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec><title>Aim</title><p>The prostate cancer (PCa) detection rate of MR-guided biopsy (MRGB) increased in our hospital from 36.6% in 2012 to 69% in 2013. The study analysed the values of the mpMRI-characteristics of identifiable lesions retrospectively to show the influence of the increasing experience of the observer and modified technical conditions.</p></sec><sec sec-type="methods"><title>Methods</title><p>56 patients (pat.) with mostly at least one prior negative TRUS-guided biopsy and persistent suspicion of PCa with at least one mpMRI-defined identifiable cancer suspicious lesion were included in this study between 2012 and 2013. MpMRI: 1.5 T/e-coil/T2WI/DWI, b-values 2012: 0-1500, 2013: 100-1500/DCE-MRI]. MRGB: in-bore. Characteristics of lesions (ADC, ESUR PIRADS) were statistically correlated with core needle biopsy results (ROC). A p value of p &#x0003c; 0.05 was considered as statistically significant.</p></sec><sec sec-type="results"><title>Results</title><p>2012/2013: detection rate of all suspicious lesions 33%/58%; in peripheral zone 45%/50%; in transitional zone 14%/67%. The ROC curve area difference was statistically significant for 2012/2013 for ADC 0.65/0.83 (P=0.008). The cut-off values [cut-off (sensitivity; specificity)]: 2012/2013: ADC 836 (0.58;0.58) / 651 (0.72;0.71); 2013: PIRADS DWI 3.5 (0.57;1.0), PIRADS DCE 3.5 (0.63;0.69), PIRADS T2 3.5 (0.71;0.86).</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Modified DWI as to exclude microcapillary perfusion effects leads to lower cut-off value and higher diagnostic value of the ADC. The increasing experience of the observer enhances the evaluation of the transitional zone. The combination of the modified technical conditions and increasing experience of the observer leads to higher sensitivity and specificity of the overall mpMRI prostate evaluation and (PCa) detection rate.</p></sec></body></article>
